# EDGAR Filing Document

**Accession Number:** 0001845711
**File Stem:** 0000950170-25-109867
**Filing Date:** 2025-8
**Character Count:** 22219
**Document Hash:** 6013d84a2f94c25d3f384f29839f8dda
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-109867.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0000950170-25-109867

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ATAI Life Sciences N.V.
- **CENTRAL INDEX KEY:** 0001840904
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93405
- **FILM NUMBER:** 251229189

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** PROF. J.H. BAVINCKLAAN 7
- **CITY:** AMSTELVEEN
- **PROVINCE COUNTRY:** P7
- **ZIP:** 1183
- **BUSINESS PHONE:** 49 89 2153 9035

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** PROF. J.H. BAVINCKLAAN 7
- **CITY:** AMSTELVEEN
- **PROVINCE COUNTRY:** P7
- **ZIP:** 1183

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATAI Life Sciences B.V.
- **DATE OF NAME CHANGE:** 20210115
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apeiron Investment Group Ltd.
- **CENTRAL INDEX KEY:** 0001845711

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** O1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** BLOCK A, APT.12
- **STREET 2:** IL-PIAZZETTA, TOWER ROAD
- **CITY:** SLIEMA
- **STATE:** O1
- **ZIP:** SLM1605
- **BUSINESS PHONE:** 44 7557 251 563

**MAIL ADDRESS:**
- **STREET 1:** BLOCK A, APT.12
- **STREET 2:** IL-PIAZZETTA, TOWER ROAD
- **CITY:** SLIEMA
- **STATE:** O1
- **ZIP:** SLM1605

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_1.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_2.pdf`

_No text found in this document._

**Attachment 3:** `ck0000000000-ex99_5.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**ATAI Life Sciences N.V.**

*(Name of Issuer)*

**Ordinary Shares, par value Euro 0.10 per share**

*(Title of Class of Securities)*

**45822R101**

*(CUSIP Number)*

**Evan S. Simpson**<br>1 New Fetter Lane<br>London X0 EC4A 1AN<br>44 20 7959-8426

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/14/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Apeiron Investment Group Ltd.** | Name of reporting person<br>**Apeiron Investment Group Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**O1** | Citizenship or place of organization<br>**O1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**55197516.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**55197516.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**55197516.00** | Aggregate amount beneficially owned by each reporting person<br>**55197516.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**23.7%** | Percent of class represented by amount in Row (11)<br>**23.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Apeiron Presight Capital Fund II, L.P.** | Name of reporting person<br>**Apeiron Presight Capital Fund II, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1799302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1799302.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Presight Capital Management I, L.L.C.** | Name of reporting person<br>**Presight Capital Management I, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1799302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1799302.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fabian Hansen** | Name of reporting person<br>**Fabian Hansen** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1799302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1799302.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Christian Angermayer** | Name of reporting person<br>**Christian Angermayer** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1303997.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**55197516.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1303997.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**55197516.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**56501513.00** | Aggregate amount beneficially owned by each reporting person<br>**56501513.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**24.3%** | Percent of class represented by amount in Row (11)<br>**24.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value Euro 0.10 per share

**(b) Name of Issuer:**
ATAI Life Sciences N.V.

**(c) Address of Issuer's Principal Executive Offices:**
Wallstrasse 16, Berlin, 2M, 10179

**Item 4. Purpose of Transaction**

Apeiron purchased 8,675,799 Ordinary Shares in connection with the PIPE Financing.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of August 14, 2025, the Reporting Persons collectively beneficially own 55,197,516 Ordinary Shares, representing approximately 23.7% of the voting rights attached to the Ordinary Shares.

The ownership percentages set forth in this Amendment No. 2 have been calculated on the basis of 232,602,562 Ordinary Shares outstanding as of August 14, 2025 (including the 18,264,840 Ordinary Shares issued in the PIPE Financing), as notified to the Reporting Persons by the Issuer, an additional 2,367,200 Ordinary Shares underlying convertible promissory notes of the Issuer (the "Convertible Notes") held by Apeiron as of August 14, 2025, and 1,303,997 vested options that are exercisable into one Ordinary share each at an exercise price of $5.68 per Ordinary Share held by Christian Angermayer as of August 14, 2025 (the "Vested Options").

**(b)**
The following table sets forth, as of August 14, 2025, the aggregate number of Ordinary Shares and percentage of Ordinary Shares beneficially owned by each of the Reporting Persons, as well as the number of Ordinary Shares as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of.

Reporting Person	                                         Amount            Percent          Sole power          Shared power                Sole power to                Shared power
                                                                           beneficially        of class           to vote or            to vote or to                       dispose                      to dispose or
                                                                            owned                                      to direct              direct the vote                 or to direct                    to direct the
                                                                                                                             the vote                                                     the disposition                disposition
Apeiron Investment Group, Ltd.                    55,197,516             23.7%                 0                        55,197,516                             0                              55,197,516
Apeiron Presight Capital Fund II, L.P.           1,799,302               0.8%                   0                        1,799,302                               0                              1,799,302
Presight Capital Management I, L.L.C.         1,799,302               0.8%                   0                        1,799,302                               0                               1,799,302
Fabian Hansen                                              1,799,302               0.8%                   0                        1,799,302	                       0                               1,799,302
Christian Angermayer                                    56,501,513             24.3%                1,303,997	   55,197,516                          1,303,997	          55,197,516

Presight II is the record holder of 1,799,302 Ordinary Shares.  Apeiron is the record holder of 51,045,214 Ordinary Shares (including the 8,675,799 Ordinary Shares purchased in the PIPE Financing) and may be deemed to beneficially own an additional 2,367,200 Ordinary Shares underlying the Convertible Notes.  Christian Angermayer may be deemed to beneficially own 1,303,997 Ordinary Shares underlying the Vested Options.

Presight Management is the general partner of Presight II. Apeiron and Fabian Hansen are the managing members of Presight Management. Christian Angermayer is the controlling shareholder of Apeiron.

As a result, each of Presight Management, Apeiron, Mr. Hansen and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Presight II, and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Apeiron.

**(c)**
Except as described in this Item 5, none of the Reporting Persons has beneficial ownership of any Ordinary Shares or, except as described in this Schedule 13D, has effected any transaction in the Ordinary Shares during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is hereby amended and supplemented by the addition of the following:

Subscription Agreement

On July 1, 2025, the Issuer entered into the Subscription Agreement with the Apeiron, pursuant to which, among other things, Apeiron agreed to purchase an aggregate of 8,675,799 Ordinary Shares in connection with the PIPE Financing, for an aggregate purchase price of approximately $19 million, on the terms and subject to the conditions set forth therein (the "Subscription Agreement").

The Subscription Agreement contains customary representations, warranties and agreements by the Issuer, customary conditions to closing and termination provisions.  The purchase and sale of the 8,675,799 Ordinary Shares pursuant to the Subscription Agreement occurred on August 14, 2025.

The foregoing description of the Subscription Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Subscription Agreement, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

Registration Rights Agreement

On July 1, 2025, the Issuer entered into a registration rights agreement with the PIPE Investors (the "Registration Rights Agreement") providing for certain registration rights with respect to Ordinary Shares held by such holders from time to time.

The Registration Rights Agreement requires the Issuer to file a registration statement under the Securities Act of 1933, as amended, providing for the resale of all or part of the registrable securities held by the parties thereto as promptly as practicable and use reasonable best efforts to cause such registration statement to be declared effective within the timelines specified therein, and thereafter to keep such registration statement effective for the periods specified therein. The Registration Rights Agreement also contains customary indemnity, exculpation and contribution obligations by the Issuer and the other parties to the Registration Rights Agreement.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

HSR Filing Letter Agreement

On July 22, 2025, Apeiron and the Issuer entered into a letter agreement pursuant to which the Issuer has agreed to reimburse Aperiron for certain reasonable and documented out-of-pocket expenses incurred by Apeiron in connection with an HSR filing with respect to Apeiron's interest in the Issuer, in an amount not to exceed $150,000 absent the prior, written consent of the Issuer for any such excess.

The foregoing description of the HSR Filing Letter Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the HSR Filing Letter Agreement, a copy of which is attached hereto as Exhibit 99.5 and is incorporated herein by reference.

Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Apeiron Investment Group Ltd.

**Signature:** /s/ Mario Frendo

**Name/Title:** Mario Frendo, Director

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Apeiron Presight Capital Fund II, L.P.

**Signature:** /s/ Fabian Hansen

**Name/Title:** Fabian Hansen, Managing Member

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Presight Capital Management I, L.L.C.

**Signature:** /s/ Fabian Hansen

**Name/Title:** Fabian Hansen, Managing Member

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fabian Hansen

**Signature:** /s/ Fabian Hansen

**Name/Title:** Fabian Hansen

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Christian Angermayer

**Signature:** /s/ Christian Angermayer

**Name/Title:** Christian Angermayer

**Date:** 08/18/2025